Sven A. Lang

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

Sven A. Lang, Andreas Gäumann, Gudrun E. Koehl et al. · International Journal of Cancer · 2007 · 167 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer

Johannes Taeger, Christian Moser, Claus Hellerbrand et al. · Molecular Cancer Therapeutics · 2011 · 142 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1α Autocrine Loop, and Reduces Orthotopic Tumor Growth

Sven A. Lang, Christian Moser, Andreas Gäumann et al. · Clinical Cancer Research · 2007 · 132 citations

Life Sciences, Biochemistry, Oncology +16

New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells

Eva Gottfried, Sven A. Lang, Kathrin Renner et al. · PLoS ONE · 2013 · 119 citations · Full text

Medicine, Oncology, Pharmacology +15

Inhibition of heat shock protein 90 impairs epidermal growth factor–mediated signaling in gastric cancer cells and reduces tumor growth and vascularization <i>in vivo</i>

Sven A. Lang, Dagmar Klein, Christian Moser et al. · Molecular Cancer Therapeutics · 2007 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17